VTGN VistaGen Therapeutics, Inc.
$0.24▼ -0.84%
Healthcare
Other
After hours
$0.24▲ +1.22%
Sep 11, 5:43 PM ET
Volume 309.8K
Avg Volume (10D) 410.7K
Key Metrics & Fundamentals
Market Cap
$10.52M
P/E Ratio
–
Div Yield
–%
52W Range
0.20 - 5.14
% vs 50 MA
-3.77%
% vs 200 MA
-70.75%
RSI-14
41.5
MACD Histogram
+0.0000
Beta (1Y vs SPY)
1.73
Free Cash Flow
-$14.71M
Gross Rev
$1.48M
Gross Profit
$1.48M
EBITDA
-$13.15M
COGS
–
Operating Exp
$14.82M
Operating Income
-$13.35M
EBIT
-$13.35M
Pretax Income
-$13.03M
Net Income
-$13.03M
EPS (Diluted)
-0.30
Price & Volume History
Loading chart…
Recent News
Vistagen to Present at Psych Congress 2026
GlobeNewswire · Sep 10, 2026 12:30 PM
Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update
GlobeNewswire · Aug 14, 2026 12:32 PM
Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
GlobeNewswire · Aug 6, 2026 12:30 PM
SRX Global (SRXH) Acquires Stake in Vistagen Therapeutics
NewMediaWire · Aug 4, 2026 7:30 PM
SRX Global Acquires Stake in Vistagen Therapeutics
InvestorsHub · Aug 4, 2026 3:35 PM
Top Premarket Gainers
MT Newswires · Aug 4, 2026 11:07 AM
SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN)
GlobeNewswire · Aug 4, 2026 9:00 AM
Vistagen Appoints Douglas J. Williamson to its Board of Directors
GlobeNewswire · Jul 31, 2026 12:30 PM
Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results?
Insider Monkey · Jul 15, 2026 9:22 AM
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Business Wire · Jun 30, 2026 12:00 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See VTGN's money flow as a full page
Social Sentiment
No Reddit posts found for VTGN.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.